Invictus MD Strategies Inc. (CSE:IMH,OTC:IVITF) has a flurry of recent developments as the company builds a portfolio of Canadian licensed producers preparing to move into the recreational market.
The global cannabis industry has taken off over the past couple of years, but the Canadian market offers the most mature opportunities. Investors have taken notice with several licensed producers reaching $100+ million market capitalizations.
Despite the significant growth in demand from consumers, there are only 38 licenses to grow, process, and/or sell medical marijuana under the ACMPR program established by Health Canada. There are many more licensed producers at various stages of approval, but the rigorous process means that it could be years before there is enough supply to meet expected domestic demand.
Invictus MD Strategies plans to capitalize on Canada's burgeoning cannabis industry by acquiring a portfolio of licensed producers and readying as much production capacity as possible to prepare for a projected shortfall of supply once marijuana is fully legalized. It has demonstrated the ability to act quickly and close deals to this point, with many announcements over the preceding four months.
Last year, the company announced the acquisition of a 33% stake in AB Laboratories Inc. On January 17, 2017 Invictus announced a binding letter of intent to acquire 100% of PlanC BioPharma. The company also announced a definitive option agreement with a third late-stage applicant to become a licensed producer on February 7, 2017.
For the full article go to FinancialContent
Read More